You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
研發費用大幅增長 三生國健(688336.SH)2020年預虧1.94-2.24億元
格隆匯 01-20 10:31

格隆匯1月20日丨三生國健(688336.SH)披露2020年年度業績預虧公吿,公司預計2020年年度實現營業收入6.00億元到7.00億元,將減少5.77億元到4.77億元,同比減少40.55%到49.04%。

公司預計2020年年度實現歸屬於母公司所有者的淨利潤-1.94億元到-2.24億元,將減少4.23億元到4.53億元,同比減少184.61%到197.69%。

公司預計2020年年度歸屬於母公司所有者的扣除非經常性損益後的淨利潤-1.92億元到-2.22億元,將減少4.85億元到5.15億元,同比減少165.58%到175.82%。

公司預計2020年年度研發費用3.36億元到3.80億元,將增加5711.07萬元到1.01億元,同比增長20.48%到36.25%。

業績變化的主要原因系:

1、由於受到新冠疫情及市場競爭加劇的影響,公司2020年銷售收入出現下滑,預計2020年年度實現營業收入6.00億元到7.00億元,將減少4.77億元到5.77億元,同比減少40.55%到49.04%;

2、為維護公司的市場競爭地位,在10月底公司對主要產品益賽普進行價格調整,益賽普25mg及12.5mg價格均調降50%,產品價格的大幅下降影響了益賽普四季度的銷售收入及毛利;

3、為推進新產品賽普汀的上市需投入較多的市場推廣費用,銷售費用增加;

4、隨着研發項目的穩步開展,研發費用亦不斷增加,2020年年度研發費用3.36億元到3.80億元,同比增長20.48%到36.25%。

綜上所述,公司2020年度出現淨利潤為負的虧損情況,相比上年同期出現較大幅度的下降。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account